Press Releases on December 7, 2020 - EIN Presswire - Press Release Distribution Service

Published on December 7, 2020 - 13:00 GMT

Sodexo Recognized for its Leadership on Climate Change by Natural Resources Defense Council and the Humane Society of the United ...

Gaithersburg, MD, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Sodexo announced today that its Better Tomorrow 2025 goal to reduce its carbon footprint by 34 percent globally, a Science-Based Target aligned with the most ambitious goal of the Paris Agreement to limit …

Distribution channels: Media, Advertising & PR, Travel & Tourism Industry ...

Published on December 7, 2020 - 13:00 GMT

Microsoft Discover AI Upskilling Journey 2020: Fostering learning, connection and growth in upcoming AI innovators

This summer, students from around the world took on Microsoft’s Discover AI Upskilling Journey to learn about AI across several industries and themes. In collaboration with Agorize, Microsoft provided over 500 participants from 39 countries with the …

Distribution channels:

Published on December 7, 2020 - 13:00 GMT

SeaSpine Announces Limited Commercial Launch of Meridian™ ALIF System with Reef™ A Interbody

CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch of its …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on December 7, 2020 - 13:00 GMT

Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice President of Medical and Clinical Affairs

DUBLIN, Ireland, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy …

Distribution channels: Media, Advertising & PR, Technology ...

Published on December 7, 2020 - 13:00 GMT

Kronos Bio Announces FDA Clearance of Investigational New Drug (IND) Application for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-...

MYC amplification found in approximately 30% of solid tumors Phase 1/2 clinical trial to begin in the first quarter of 2021 KB-0742 generated using the company’s proprietary small molecule microarray (SMM) screening platform SAN MATEO, Calif., and …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on December 7, 2020 - 13:00 GMT

Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma

NEWARK, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported initial results of a Phase I trial (https:// …

Distribution channels: Media, Advertising & PR, Technology ...

Published on December 7, 2020 - 13:00 GMT

Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable Written Opinion of the International Search ...

DUBLIN, Ireland and CHICAGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi- …

Distribution channels: Healthcare & Pharmaceuticals Industry, Law ...

Published on December 7, 2020 - 13:00 GMT

Reputation.com Breaks New Ground in Reputation Experience Management With Reputation Score X

REDWOOD CITY, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Reputation.com, provider of the first — and only — complete Reputation Experience Management (RXM) platform, today unveiled Reputation Score X, a next-generation reputation measurement tool that …

Distribution channels: IT Industry, Media, Advertising & PR ...

Published on December 7, 2020 - 13:00 GMT

SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal ...

6-month Priority Review granted for ibrexafungerp with PDUFA target action date set for June 1, 2021 FDA indicated that it is not currently planning to hold an advisory committee meeting for the application SCYNEXIS is continuing preparations for a U.S. …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on December 7, 2020 - 13:00 GMT

Beyond Air® Initiates Patient Screening for LungFit™ GO Pilot Study for At-Home, Self-Administration of Inhaled Nitric Oxide in ...

Expect to dose first patient in January 2021 and report interim data mid-2021 Success in nontuberculous mycobacteria (NTM) at-home study paves the way to enter the much broader market treating severe lung infections in the home GARDEN CITY, N.Y., Dec. 07, …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on December 7, 2020 - 13:00 GMT

Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell Function at the 2020 American Society ...

LA JOLLA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, presented data over the weekend demonstrating the impact of …

Distribution channels: Conferences & Trade Fairs, Culture, Society & Lifestyle ...

Published on December 7, 2020 - 13:00 GMT

Cannabis Global Inc (CBGL) and Marijuana Company of America (MCOA) Comment on Congressional Action Toward Marijuana Legalization - ...

LOS ANGELES, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Cannabis Global, Inc. (OTC: CBGL), an innovation-oriented company investing in disruptive cannabis and hemp-related technologies and Marijuana Company of America (MCOA) today issued statements concerning the …

Distribution channels:

Published on December 7, 2020 - 13:00 GMT

ORYZON Presents New Robust Phase II Iadademstat Efficacy Data in AML at ASH-2020

Robust signals of clinical efficacy, with ORR of 85%, of which 64% are CR/CRi Longest remission to date 690 days, still ongoing 86% of CR/CRi show a duration of response of more than 6 months Iadademstat and azacitidine combination shows a good safety …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on December 7, 2020 - 13:00 GMT

DLH Reports Fourth Quarter and Fiscal Year 2020 Results

ATLANTA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare services and solutions to federal agencies, today announced financial results for its fiscal fourth quarter …

Distribution channels: Business & Economy, Culture, Society & Lifestyle ...

Published on December 7, 2020 - 13:00 GMT

RevoluGROUP Canada Inc. Granted Canadian FINTRAC License

VANCOUVER, British Columbia, Dec. 07, 2020 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2) (the "Company") is pleased to announce that The Financial Transactions and Reports Analysis Centre of Canada (FINTRAC) has …

Distribution channels:

Published on December 7, 2020 - 13:00 GMT

MiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference

MARIETTA, Ga., Dec. 07, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will present at the 39th Annual J …

Distribution channels:

Published on December 7, 2020 - 13:00 GMT

Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with ...

DARE-BV1 met the primary endpoint of the study and all pre-specified secondary efficacy endpoints; demonstrated significantly greater clinical cure rates compared to placebo DARE-BV1 has Fast Track and QIDP designations from FDA New drug application (NDA) …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on December 7, 2020 - 13:00 GMT

Acutus Medical Launches AcQBlate® Force Sensing Ablation System in Europe

CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the launch of the AcQBlate® Force Sensing …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on December 7, 2020 - 13:00 GMT

scPharmaceuticals Inc. Receives Complete Response Letter from FDA for FUROSCIX®

BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient …

Distribution channels: Media, Advertising & PR, Technology ...

Published on December 7, 2020 - 13:00 GMT

Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ...

Best objective response rate of 87% reported for 15 patients with relapsed/refractory mantle cell lymphoma, with a median follow-up of 12.1 months. Median progression-free survival (PFS) was not reached The combination of cirmtuzumab and ibrutinib has been …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...